Latest Filings

Issuer Activity

Insider Overview :: Tekmira Pharmaceuticals Corporation (T:TKM) [?]
Business Focus: Biotechnology & Medical Research
Recent Price for TKM
CAD 4.85 0.00 (0.00%)
TSX Delayed 15 minutes
May 22 1600 EDT
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
N/A 6.49 2.8 N/A 69.73
1-Day Low 52-Week Low Yield Avg. Volume  
N/A 1.92 0.0% 26,752  
Log in or sign up for a free account to add this stock to your watch list.
Holdings trends & enhanced charts available in PDF report. Click here for details »
Latest 10 SEDI filings (by transaction date) for TKM within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 22nd, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
Apr 18/13 Apr 16/13 Murray, Mark Joseph Direct Ownership Common Shares 10 - Acquisition in the public market 5,000 $4.60
USD
Mar 19/13 Mar 12/13 Jewell, Donald Direct Ownership Common Shares 10 - Acquisition in the public market 1,200 $4.44
Mar 15/13 Mar 7/13 Gardiner, Diane Kathleen Direct Ownership Options 50 - Grant of options 15,000 $4.54
Mar 15/13 Mar 6/13 Gardiner, Diane Kathleen Direct Ownership Options 00 - Opening Balance-Initial SEDI Report    
Mar 5/13 Feb 15/13 Abrams, Michael Jeffery Direct Ownership Common Shares 51 - Exercise of options 675 $0.444
Mar 5/13 Feb 15/13 Abrams, Michael Jeffery Direct Ownership Options 51 - Exercise of options -675 $0.444
Feb 6/13 Feb 1/13 Jewell, Donald Direct Ownership Common Shares 10 - Acquisition in the public market 5,500 $4.73
Dec 11/12 Dec 10/12 Galbraith, Kenneth H. Direct Ownership Options 50 - Grant of options 5,000 $5.15
Dec 11/12 Dec 10/12 Jewell, Donald Direct Ownership Options 50 - Grant of options 5,000 $5.15
Dec 11/12 Dec 10/12 Karbe, Lutz Frank Direct Ownership Options 50 - Grant of options 5,000 $5.15
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Latest 10 SEDI filings (by filing date) for TKM within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 22nd, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
Apr 18/13 Apr 16/13 Murray, Mark Joseph Direct Ownership Common Shares 10 - Acquisition in the public market 5,000 $4.60
USD
Mar 19/13 Mar 12/13 Jewell, Donald Direct Ownership Common Shares 10 - Acquisition in the public market 1,200 $4.44
Mar 15/13 Mar 7/13 Gardiner, Diane Kathleen Direct Ownership Options 50 - Grant of options 15,000 $4.54
Mar 15/13 Mar 6/13 Gardiner, Diane Kathleen Direct Ownership Options 00 - Opening Balance-Initial SEDI Report    
Mar 5/13 Feb 15/13 Abrams, Michael Jeffery Direct Ownership Common Shares 51 - Exercise of options 675 $0.444
Mar 5/13 Feb 15/13 Abrams, Michael Jeffery Direct Ownership Options 51 - Exercise of options -675 $0.444
Feb 6/13 Feb 1/13 Jewell, Donald Direct Ownership Common Shares 10 - Acquisition in the public market 5,500 $4.73
Dec 11/12 Dec 10/12 Galbraith, Kenneth H. Direct Ownership Options 50 - Grant of options 5,000 $5.15
Dec 11/12 Dec 10/12 Jewell, Donald Direct Ownership Options 50 - Grant of options 5,000 $5.15
Dec 11/12 Dec 10/12 Karbe, Lutz Frank Direct Ownership Options 50 - Grant of options 5,000 $5.15
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider.
No Markers (TSX Insider Summaries) for TKM on May 22, 2013 [?]
To view marker data for the past week, sign up for an account or log in above.
To view more history, sign up for an account at inkresearch.com
Sector:  Healthcare Industry:  Biotechnology & Medical Research
Key People
Daniel L. Kisner
Independent Chairman of the Board 		Mark J. Murray
President, Chief Executive Officer, Director 		Ian C. Mortimer
Chief Financial Officer, Executive Vice President - Finance
Ian MacLachlan
Executive Vice President, Chief Scientific Officer 		Paul A. Brennan
Senior Vice President - Business Development 		Peter Lutwyche
Senior Vice President - Pharmaceutical Development
R. Hector MacKay-Dunn
Corporate Secretary 		   
Company Contact
Address: Suite 100, 8900 Glenlyon Parkway
BURNABY BC V5J 5J8
Tel: 1-604-4193200
Website: www.tekmirapharm.com
IR: investor.tekmirapharm.com/index.cfm
Business Overview
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. On March 1, 2012, it announced that the Company had secured a license from Alnylam to develop TKMALDH2, an RNAi therapeutic that utilizes Tekmira's LNP for the treatment of Alcohol Dependence (AD). Its lead oncology product candidate, TKM-PLK1, targets PLK1, a protein involved in tumor cell proliferation and a validated oncology target. On February 8, 2012, it announced that Phase I clinical trial for TKM-Ebola had been initiated. The Phase 1 TKM-Ebola clinical trial is a placebo-controlled, single-blind, single-ascending dose study with additional multiple-ascending dose cohorts in healthy human volunteers. In the field of RNAi therapeutics, the Company has licensed its LNP delivery technology to Alnylam Pharmaceuticals, Inc. and Merck & Co., Inc.
Competitors with Recent Insider Filings
QLT (T:QLT)
EnWave (V:ENW)
iCo Therapeutics (V:ICO)
 
Tekmira Pharmaceuticals Corporation Insider Report Only $20.00